Carina Kern
Dr. Kern is the CEO of LinkGevity, an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. With a distinguished background in Molecular Biology, Pharmacology, Evolutionary Biology, and Genetics, she is renowned for her pioneering work on aging mechanisms and lifespan extension. Her labs are based at the Babraham Research Campus, affiliated with the University of Cambridge, UK. Her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with backing from UK Government, The Francis Crick Institute KQ labs, and European Union (Horizon). The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.
LinkGevity
Space Therapies: Accelerating Biotech Solutions for Health Beyond Earth
-
Space is among the harshest and least hospitable environments for humans. Every human biological system is affected by the space environment. The biological stress has a deleterious impact on health and physical capabilities, and the extreme conditions and isolation take a significant toll on mental performance and behavior. By 2040, hundreds of people will be in space at any given time, and more than 80% of those are predicted to be private citizens; for the reliability, safety, health, and enjoyment of those private participants, new solutions and therapeutics are needed to maintain health and wellbeing.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
